Cargando…

Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis

BACKGROUND: Magnetic resonance imaging (MRI) may guide breast cancer surgery by measuring residual tumor size post-neoadjuvant chemotherapy (NAC). Accurate measurement may avoid overly radical surgery or reduce the need for repeat surgery. This individual patient data (IPD) meta-analysis examines MR...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinovich, Michael L., Macaskill, Petra, Irwig, Les, Sardanelli, Francesco, Mamounas, Eleftherios, von Minckwitz, Gunter, Guarneri, Valentina, Partridge, Savannah C., Wright, Frances C., Choi, Jae Hyuck, Bhattacharyya, Madhumita, Martincich, Laura, Yeh, Eren, Londero, Viviana, Houssami, Nehmat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599727/
https://www.ncbi.nlm.nih.gov/pubmed/26449630
http://dx.doi.org/10.1186/s12885-015-1664-4
_version_ 1782394306104918016
author Marinovich, Michael L.
Macaskill, Petra
Irwig, Les
Sardanelli, Francesco
Mamounas, Eleftherios
von Minckwitz, Gunter
Guarneri, Valentina
Partridge, Savannah C.
Wright, Frances C.
Choi, Jae Hyuck
Bhattacharyya, Madhumita
Martincich, Laura
Yeh, Eren
Londero, Viviana
Houssami, Nehmat
author_facet Marinovich, Michael L.
Macaskill, Petra
Irwig, Les
Sardanelli, Francesco
Mamounas, Eleftherios
von Minckwitz, Gunter
Guarneri, Valentina
Partridge, Savannah C.
Wright, Frances C.
Choi, Jae Hyuck
Bhattacharyya, Madhumita
Martincich, Laura
Yeh, Eren
Londero, Viviana
Houssami, Nehmat
author_sort Marinovich, Michael L.
collection PubMed
description BACKGROUND: Magnetic resonance imaging (MRI) may guide breast cancer surgery by measuring residual tumor size post-neoadjuvant chemotherapy (NAC). Accurate measurement may avoid overly radical surgery or reduce the need for repeat surgery. This individual patient data (IPD) meta-analysis examines MRI’s agreement with pathology in measuring the longest tumor diameter and compares MRI with alternative tests. METHODS: A systematic review of MEDLINE, EMBASE, PREMEDLINE, Database of Abstracts of Reviews of Effects, Heath Technology Assessment, and Cochrane databases identified eligible studies. Primary study authors supplied IPD in a template format constructed a priori. Mean differences (MDs) between tests and pathology (i.e. systematic bias) were calculated and pooled by the inverse variance method; limits of agreement (LOA) were estimated. Test measurements of 0.0 cm in the presence of pathologic residual tumor, and measurements >0.0 cm despite pathologic complete response (pCR) were described for MRI and alternative tests. RESULTS: Eight studies contributed IPD (N = 300). The pooled MD for MRI was 0.0 cm (LOA: +/−3.8 cm). Ultrasound underestimated pathologic size (MD: −0.3 cm) relative to MRI (MD: 0.1 cm), with comparable LOA. MDs were similar for MRI (0.1 cm) and mammography (0.0 cm), with wider LOA for mammography. Clinical examination underestimated size (MD: −0.8 cm) relative to MRI (MD: 0.0 cm), with wider LOA. Tumors “missed” by MRI typically measured 2.0 cm or less at pathology; tumors >2.0 cm were more commonly “missed” by clinical examination (9.3 %). MRI measurements >5.0 cm occurred in 5.3 % of patients with pCR, but were more frequent for mammography (46.2 %). CONCLUSIONS: There was no systematic bias in MRI tumor measurement, but LOA are large enough to be clinically important. MRI’s performance was generally superior to ultrasound, mammography, and clinical examination, and it may be considered the most appropriate test in this setting. Test combinations should be explored in future studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1664-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4599727
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45997272015-10-10 Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis Marinovich, Michael L. Macaskill, Petra Irwig, Les Sardanelli, Francesco Mamounas, Eleftherios von Minckwitz, Gunter Guarneri, Valentina Partridge, Savannah C. Wright, Frances C. Choi, Jae Hyuck Bhattacharyya, Madhumita Martincich, Laura Yeh, Eren Londero, Viviana Houssami, Nehmat BMC Cancer Research Article BACKGROUND: Magnetic resonance imaging (MRI) may guide breast cancer surgery by measuring residual tumor size post-neoadjuvant chemotherapy (NAC). Accurate measurement may avoid overly radical surgery or reduce the need for repeat surgery. This individual patient data (IPD) meta-analysis examines MRI’s agreement with pathology in measuring the longest tumor diameter and compares MRI with alternative tests. METHODS: A systematic review of MEDLINE, EMBASE, PREMEDLINE, Database of Abstracts of Reviews of Effects, Heath Technology Assessment, and Cochrane databases identified eligible studies. Primary study authors supplied IPD in a template format constructed a priori. Mean differences (MDs) between tests and pathology (i.e. systematic bias) were calculated and pooled by the inverse variance method; limits of agreement (LOA) were estimated. Test measurements of 0.0 cm in the presence of pathologic residual tumor, and measurements >0.0 cm despite pathologic complete response (pCR) were described for MRI and alternative tests. RESULTS: Eight studies contributed IPD (N = 300). The pooled MD for MRI was 0.0 cm (LOA: +/−3.8 cm). Ultrasound underestimated pathologic size (MD: −0.3 cm) relative to MRI (MD: 0.1 cm), with comparable LOA. MDs were similar for MRI (0.1 cm) and mammography (0.0 cm), with wider LOA for mammography. Clinical examination underestimated size (MD: −0.8 cm) relative to MRI (MD: 0.0 cm), with wider LOA. Tumors “missed” by MRI typically measured 2.0 cm or less at pathology; tumors >2.0 cm were more commonly “missed” by clinical examination (9.3 %). MRI measurements >5.0 cm occurred in 5.3 % of patients with pCR, but were more frequent for mammography (46.2 %). CONCLUSIONS: There was no systematic bias in MRI tumor measurement, but LOA are large enough to be clinically important. MRI’s performance was generally superior to ultrasound, mammography, and clinical examination, and it may be considered the most appropriate test in this setting. Test combinations should be explored in future studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1664-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-08 /pmc/articles/PMC4599727/ /pubmed/26449630 http://dx.doi.org/10.1186/s12885-015-1664-4 Text en © Marinovich et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Marinovich, Michael L.
Macaskill, Petra
Irwig, Les
Sardanelli, Francesco
Mamounas, Eleftherios
von Minckwitz, Gunter
Guarneri, Valentina
Partridge, Savannah C.
Wright, Frances C.
Choi, Jae Hyuck
Bhattacharyya, Madhumita
Martincich, Laura
Yeh, Eren
Londero, Viviana
Houssami, Nehmat
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
title Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
title_full Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
title_fullStr Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
title_full_unstemmed Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
title_short Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
title_sort agreement between mri and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599727/
https://www.ncbi.nlm.nih.gov/pubmed/26449630
http://dx.doi.org/10.1186/s12885-015-1664-4
work_keys_str_mv AT marinovichmichaell agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT macaskillpetra agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT irwigles agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT sardanellifrancesco agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT mamounaseleftherios agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT vonminckwitzgunter agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT guarnerivalentina agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT partridgesavannahc agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT wrightfrancesc agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT choijaehyuck agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT bhattacharyyamadhumita agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT martincichlaura agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT yeheren agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT londeroviviana agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis
AT houssaminehmat agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis